search
Back to results

Prismatic Lenses in the Pisa Syndrome

Primary Purpose

Pisa Syndrome, Parkinson' Disease

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
glasses (prismatic lenses)
glasses (neutral)
Sponsored by
Neuromed IRCCS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pisa Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged ≥ 18 years
  • Diagnosis of PD according to the diagnostic criteria of the United Kingdom Brain Bank with or without dementia (but with MMSE> 14)
  • Hoehn-Yahr Stadium from 1 to 4
  • Signature of Informed Consent and the privacy form

Exclusion Criteria:

  • Patients with morphostructural changes in the spine that exclude the diagnosis of PS.
  • Patients with symptoms and signs compatible with atypical parkinsonism
  • Patients affecd by PD treated with antagonist drugs for central dopaminergic receptors (first generation antipsychotics and second generation with the exception of clozapine and quetiapine, antiemetic, prokinetic, etc.) in the last 6 months before enrollment
  • Patients with a history of major spinal surgery (tumors, infections, ankylosing spondylitis, paraneoplastic syndromes)
  • Other neurological diseases.
  • Patients with manifested disorders of eeye movement disorders prior to the diagnosis of PD
  • Patents with abnormalities of normal binocular vision
  • Patients with amblyopia, medium or high anisometropy,
  • Patients with a binocular vision acuity less than 7/10
  • Patients with evolved cataracts
  • Pateints with glaucoma
  • Patients with active maculopathies
  • Patients with severe mono or binocular visual field depressions of different origins Patients with astigmatisms higher than 3 dioptres, hypermetropias or myopias greater than 3 dioptres

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    group prisms

    group placebo lenses

    Arm Description

    Patients that receive active prismatic lenses

    Patients that receive non-active prismatic lenses

    Outcomes

    Primary Outcome Measures

    Determine the change of dystonia in Pisa syndrome with the use of prisms
    Verify the possible variation of dystonia in patients affected by Pisa Syndrome after the use for a month of prismatic lenses prescribed during the randomization phase with the aid of a wall protractor through the recording of the amount of dystonia measured in degrees with the patient positioned against the wall against a dedicated protractor. This measurement is photographed.
    Determine the kinematic variation in Pisa Syndrome with the use of prisms
    Verify the static and dynamic kinematic variation in patients affected by Pisa Syndrome after the use for a month of prismatic lenses prescribed during the randomization phase and according to the following protocol: 30 seconds stationary in orthostatic position, shoulders to the cameras, about 5 steps forward, stationary in orthostatic position while fixing visual stimulation points placed on the wall, 30 second stationary in an orthostatic position after having covered a section of the corridor in front of the kinematic evaluation room.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 30, 2018
    Last Updated
    November 7, 2018
    Sponsor
    Neuromed IRCCS
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03737773
    Brief Title
    Prismatic Lenses in the Pisa Syndrome
    Official Title
    Randomized Double-blind Study on the Effect of Orthoptic Rehabilitation in Pisa Syndrome Associated With Parkinson's Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2016 (Actual)
    Primary Completion Date
    July 2017 (Actual)
    Study Completion Date
    October 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Neuromed IRCCS

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Non-pharmacological interventional pilot study on the effect of prismatic glasses for the improvement of Pisa syndrome in Parkinson's disease. The study involves 40 patients, of whom 20 receive active treatment and 20 slow placebo. At the end of the study, all patients receive corrective lenses in compassionate use if the study yields positive results.
    Detailed Description
    In previous cases of patients with Parkinson's disease and Pisa Syndrome, the investigators found a slight improvement in the dystonia of the trunk after the application of prismatic lenses. The current study provides the involvement of 40 patients with Parkinson's disease, of which twenty treated with permanent prismatic optical correction, and twenty treated with neutral optical correction or with the only optical correction of the refractive basic defects (placebo). The protocol provides the collection of these data: Personal data (date of birth, sex, marital status, profession) General history (weight, height, non-neurological and neurological concomitant pathologies, medical conditions that may be associated or predisposing patients to PS, non-antiparkinsonian therapy in progress) Specific history for PD (year from the first diagnosis of PD, year of appearance of the first motor symptoms of PD, type and distribution of motor symptoms at the onset) Pharmacological history of PD (year of initiation of the first treatment for PD, which drugs (s), antiparkinsonian therapy in progress) Neurological Evaluation in ON: UPDRS I, II, III and IV (III: also items-20-26 right and left side), Hoehn-Yahr stage; Specific history for PS; Detection of some information about the patients' perception of having the torso tilted sideways, direction of inclination, how long it is present, how long it is manifested, conditions in which this inclination is present (standing, sitting, etc.) ) Presence of low back pain and pain intensity measured with the Visual Analogue Scale (VAS). Clinical and kinematic evaluation of PS: The amount of dystonia measured in degrees with the patient positioned against the wall against a dedicated protractor. This measurement is photographed. Static and dynamic kinematic evaluation (gait analysis) according to the following protocol: 30 seconds stationary in orthostatic position, shoulders to the cameras, about 5 steps forward, stationary in orthostatic position while fixing visual stimulation points placed on the wall, 30 second stationary in an orthostatic position after having covered a section of the corridor in front of the kinematic evaluation room. Orthoptic evaluation: complete orthoptic evaluation and prescription of personalized prismatic lenses, randomizing the patient on active or slow-moving placebo lenses with respect to the other experimenters and the patient. Flowchart of visits: Screening: the neurologist selects the patient according to the eligibility criteria indicated above and verifies the patient's willingness to participate. Randomization: the patient undergoes clinical and kinematics evaluation of the PS, orthoptic examination and randomization on active lenses and placebo. Study times: T0: randomization and prescription of lenses T1: check after 1 month from the use of lenses Patients are recruited at the Parkinson's Center of the IRCCS Neuromed.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pisa Syndrome, Parkinson' Disease

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    40 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    group prisms
    Arm Type
    Active Comparator
    Arm Description
    Patients that receive active prismatic lenses
    Arm Title
    group placebo lenses
    Arm Type
    Placebo Comparator
    Arm Description
    Patients that receive non-active prismatic lenses
    Intervention Type
    Other
    Intervention Name(s)
    glasses (prismatic lenses)
    Intervention Type
    Other
    Intervention Name(s)
    glasses (neutral)
    Primary Outcome Measure Information:
    Title
    Determine the change of dystonia in Pisa syndrome with the use of prisms
    Description
    Verify the possible variation of dystonia in patients affected by Pisa Syndrome after the use for a month of prismatic lenses prescribed during the randomization phase with the aid of a wall protractor through the recording of the amount of dystonia measured in degrees with the patient positioned against the wall against a dedicated protractor. This measurement is photographed.
    Time Frame
    1 month
    Title
    Determine the kinematic variation in Pisa Syndrome with the use of prisms
    Description
    Verify the static and dynamic kinematic variation in patients affected by Pisa Syndrome after the use for a month of prismatic lenses prescribed during the randomization phase and according to the following protocol: 30 seconds stationary in orthostatic position, shoulders to the cameras, about 5 steps forward, stationary in orthostatic position while fixing visual stimulation points placed on the wall, 30 second stationary in an orthostatic position after having covered a section of the corridor in front of the kinematic evaluation room.
    Time Frame
    1 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients aged ≥ 18 years Diagnosis of PD according to the diagnostic criteria of the United Kingdom Brain Bank with or without dementia (but with MMSE> 14) Hoehn-Yahr Stadium from 1 to 4 Signature of Informed Consent and the privacy form Exclusion Criteria: Patients with morphostructural changes in the spine that exclude the diagnosis of PS. Patients with symptoms and signs compatible with atypical parkinsonism Patients affecd by PD treated with antagonist drugs for central dopaminergic receptors (first generation antipsychotics and second generation with the exception of clozapine and quetiapine, antiemetic, prokinetic, etc.) in the last 6 months before enrollment Patients with a history of major spinal surgery (tumors, infections, ankylosing spondylitis, paraneoplastic syndromes) Other neurological diseases. Patients with manifested disorders of eeye movement disorders prior to the diagnosis of PD Patents with abnormalities of normal binocular vision Patients with amblyopia, medium or high anisometropy, Patients with a binocular vision acuity less than 7/10 Patients with evolved cataracts Pateints with glaucoma Patients with active maculopathies Patients with severe mono or binocular visual field depressions of different origins Patients with astigmatisms higher than 3 dioptres, hypermetropias or myopias greater than 3 dioptres
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nicola Modugno, MD, PHD
    Organizational Affiliation
    Neuromed IRCCS
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Prismatic Lenses in the Pisa Syndrome

    We'll reach out to this number within 24 hrs